Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperpolarized Pyruvate (13C) MRI in Prostate Cancer
NCT02647983Phase 1Withdrawn
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Apr 2016
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [1-13C]pyruvate in prostate cancer (PCa), sponsored by Sunnybrook Health Sciences Centre. Primary endpoint: Ability of the MRI machine to produce an image of the participant's prostate at 2 years. Planned start Apr 2016; status: withdrawn.
02
Drugs
[1-13C]pyruvate
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02647983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02647983.